Vistagen Therapeutics Inc
(VTGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2014 | 05-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 401 | 0 | N/A | N/A | 7 |
| TOTAL | $555 | $41 | $41 | $41 | $154 |
| Non-Current Assets | |||||
| PPE Net | 163 | 176 | 176 | 176 | 205 |
| Other Non-Current Assets | 47 | 47 | 47 | 47 | 47 |
| TOTAL | $210 | $223 | $223 | $223 | $252 |
| Total Assets | $765 | $264 | $264 | $264 | $406 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,348 | 396 | 396 | 396 | 7 |
| Accounts payable and accrued liabilities | 1,901 | 2,444 | 2,444 | 2,444 | 1,984 |
| Accrued Expenses | 810 | 626 | 626 | 626 | 462 |
| Other current liabilities | N/A | 4 | 4 | 4 | 30 |
| TOTAL | $6,197 | $5,206 | $5,206 | $5,206 | $3,253 |
| Non-Current Liabilities | |||||
| Long Term Debt | 3,056 | 2,855 | 2,855 | 2,855 | 3,517 |
| Other Non-Current Liabilities | 6,805 | 4,904 | 4,904 | 4,904 | 6,305 |
| TOTAL | $9,959 | $7,858 | $7,858 | $7,858 | $9,907 |
| Total Liabilities | $16,155 | $13,064 | $13,064 | $13,064 | $13,160 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 851 | N/A | 848 | 778 | 739 |
| Common Shares | 28 | 1 | 1 | 1 | 25 |
| Retained earnings | -75,190 | -70,637 | -70,637 | -70,637 | -68,943 |
| Other shareholders' equity | -166 | -166 | -166 | -166 | -172 |
| TOTAL | $-15,391 | $-12,800 | $-12,800 | $-12,800 | $-12,754 |
| Total Liabilities And Equity | $765 | $264 | $264 | $264 | $406 |